Mifepristone REMS Prescribing Requirements
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2025-01-23 — SAVE Moms and Babies Act of 2025: cross-connection with save-moms-and-babies-act: SAVE Moms and Babies Act would statutorily codify and tighten mifepristone-class REMS-style controls (in-person dispensing, prescriber certification, surgical-backup capacity), locking in restrictions that FDA REMS policy has been moving to relax. (novelty: 3)
- 2026-06-24 — To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.: HR9421 (119th Congress) introduced and referred to House Energy and Commerce (2026-06-24); would bar REMS-certified providers from prescribing mifepristone without an in-person patient visit and a medical license in the patient’s state of residence, effectively ending telehealth and cross-state mail-order prescribing. (novelty: 2)
Open questions
Related
Contributing findings
To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
24-jun-2026
novelty 2
per-area 2
introduces